Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W Fried

Showing results (41-50 of 166) with videos related to

Pageof 17
Sort By:
Pilot and Feasibility Studies|July 10, 2018
Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis CDonna M Evon, Carol E Golin, Rachel Ruffin, et al.
Journal of Psychosomatic Research|October 18, 2011
Social support and clinical outcomes during antiviral therapy for chronic hepatitis CDonna M Evon, Denise A Esserman, Darmendra Ramcharran, et al.
Clinical Liver Disease|June 17, 2021
Killing Two Birds With No StoneJane Giang, Dawn S Harrison, Benjamin K Hansen, et al.
Gastroenterology|September 6, 2006
Hemophilic siblings with chronic hepatitis C: Familial aggregation of spontaneous and treatment-related viral clearanceMichael W Fried, Barbara L Kroner, Liliana R Preiss, et al.
Gastroenterology|June 14, 2003
Severe villus atrophy and chronic malabsorption induced by azathioprineThomas R Ziegler, Concepción Fernández-Estívariz, Li H Gu, et al.
Hepatology (Baltimore, Md.)|January 22, 2011
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture modelsEmmanuel Thomas, Jordan J Feld, Qisheng Li, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 8, 2015
High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activitySusanne Johansson, Willem Talloen, Marianne Tuefferd, et al.
Scandinavian Journal of Gastroenterology|March 1, 2007
Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirinGraham R Foster, Michael W Fried, Stephanos J Hadziyannis, et al.
Gastroenterology|August 1, 2017
Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting AntiviralsPoonam Mishra, Jeffry Florian, Joy Peter, et al.
The American Journal of Gastroenterology|July 20, 2011
A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatmentDonna M Evon, Kelly Simpson, Scott Kixmiller, et al.
Pageof 17

Showing results (41-50 of 166) with videos related to

Sort By:
Pageof 17
Pilot and Feasibility Studies|July 10, 2018
Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis CDonna M Evon, Carol E Golin, Rachel Ruffin, et al.
Journal of Psychosomatic Research|October 18, 2011
Social support and clinical outcomes during antiviral therapy for chronic hepatitis CDonna M Evon, Denise A Esserman, Darmendra Ramcharran, et al.
Clinical Liver Disease|June 17, 2021
Killing Two Birds With No StoneJane Giang, Dawn S Harrison, Benjamin K Hansen, et al.
Gastroenterology|September 6, 2006
Hemophilic siblings with chronic hepatitis C: Familial aggregation of spontaneous and treatment-related viral clearanceMichael W Fried, Barbara L Kroner, Liliana R Preiss, et al.
Gastroenterology|June 14, 2003
Severe villus atrophy and chronic malabsorption induced by azathioprineThomas R Ziegler, Concepción Fernández-Estívariz, Li H Gu, et al.
Hepatology (Baltimore, Md.)|January 22, 2011
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture modelsEmmanuel Thomas, Jordan J Feld, Qisheng Li, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 8, 2015
High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activitySusanne Johansson, Willem Talloen, Marianne Tuefferd, et al.
Scandinavian Journal of Gastroenterology|March 1, 2007
Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirinGraham R Foster, Michael W Fried, Stephanos J Hadziyannis, et al.
Gastroenterology|August 1, 2017
Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting AntiviralsPoonam Mishra, Jeffry Florian, Joy Peter, et al.
The American Journal of Gastroenterology|July 20, 2011
A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatmentDonna M Evon, Kelly Simpson, Scott Kixmiller, et al.
Pageof 17